ELI-002 2P
ELI-002-001
Phase 1 small_molecule completed
Quick answer
ELI-002 2P for Minimal Residual Disease is a Phase 1 program (small_molecule) at Elicio Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Elicio Therapeutics
- Indication
- Minimal Residual Disease
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed